Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

20103,258 citationsJournal Articlebronze Open Access

Authors

Arun J. Sanyal · Virginia Commonwealth University

Naga Chalasani · Indiana University – Purdue University Indianapolis

Kris V. Kowdley · Virginia Mason Medical Center

Arthur J. McCullough · Case Western Reserve University

Anna Mae Diehl · Duke University

Nathan M. Bass · University of California, San Francisco

Brent A. Neuschwander‐Tetri

Abstract

Vitamin E was superior to placebo for the treatment of nonalcoholic steatohepatitis in adults without diabetes. There was no benefit of pioglitazone over placebo for the primary outcome; however, significant benefits of pioglitazone were observed for some of the secondary outcomes. (ClinicalTrials.gov number, NCT00063622.)

Topics & Keywords

Liver Disease Diagnosis and Treatment Diet, Metabolism, and Disease Lipid metabolism and disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 362, Issue 18, pp. 1675-1685

DOI: 10.1056/nejmoa0907929

Field-Weighted Citation Impact: 96.31